Catalyst
Slingshot members are tracking this event:
Phase I safety data on VX-152 / VX-440 expected in second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX | Community voting in process | |||||
Additional Information
Ongoing Phase 1 studies in healthy volunteers: Vertex's two next-generation correctors known as VX-152 and VX-440 are being evaluated alone and as part of a triple combination with VX-661 and ivacaftor in ongoing Phase 1 studies in healthy volunteers. Pending data from the Phase 1 studies, the company expects to begin Phase 2 clinical development in people with CF to evaluate one or both of the next-generation correctors with VX-661 and ivacaftor in the second half of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 18, 2017
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1033559
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Vx-152, Vx-440, Cf
